Smooth muscle alpha-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. (2010) Shi J, Sun M, Vogt PK. OncoTarget, 1(1):9-21.

  1. Oncotarget is an open access journal. You can access the article on their website.

Pubmed


Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. (2010) Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, Lindquist J, Acevedo LM, Anand S, Majeti BK, Tsigelny I, Saldanha A, Walsh B, Hoffman RM, Bouvet M, Klemke RL, Vogt PK, Arnold L, Wrasidlo W, Cheresh DA. Proc Natl Acad Sci U S A, 107(9):4299-304.

Pubmed


Phosphatidylinositol 3-Kinase: The Oncoprotein. (2010) Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A. Curr Top Microbiol Immunol, 347:79-104.

Pubmed


PI3K: From the Bench to the Clinic and Back. (2010) Vanhaesebroeck B, Vogt PK, Rommel C. Curr Top Microbiol Immunol, 347:1-19.

Pubmed


Long antisense non-coding RNAs and their role in transcription and oncogenesis. (2010) Morris KV, Vogt PK. Cell Cycle, 9(13), 2544 - 2547.

Pubmed


Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. (2010) Dannemann N, Hart JR, Ueno L, Vogt PK. Int J Cancer, 127(1):239-44.

Pubmed


Oncogenes and the Revolution in Cancer Research - Homage to Hidesaburo Hanafusa (1929 - 2009). (2010) Vogt PK. Genes & Cancer, 1(1):6-11.

 Pubmed


Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (PI3K): differential interactions with the regulatory subunit p85 and with RAS. (2010) Zhao L, Vogt PK. Cell Cycle, 9(3):596-600.

Pubmed


Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. (2010) Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. Proc Natl Acad Sci U S A, 107(35):15547-52.

Pubmed


Therapeutic Targeting of Myc. (2010) Prochownik E, Vogt PK. Genes & Cancer, 1(6):650-9.

 Pubmed

 

2011